Tuesday, April 22, 2014 8:14:41 PM
Investor's are waiting for the conference call to hear about the cost of the solvaldi drug. They are worried that they may not be able to maintain the price of solvaldi because law makers questioned the high cost. However, I think it's just all noise because sovaldi represents a major advance over existing treatments for hepatitis C. The new therapy can avoid the long-term medical expenses related to liver failure, cancer and transplants. I believe Gilead will be able to explain that to lawmakers and make them understand. If (I think when) this issue clears up, then this stock will explode to $100 IMO. I can't think of another company that has absolutely destroyed estimates like Gilead did this quarter. It's just absolutely amazing to see.
2014 PE just dropped to under 15 based on these earnings and rest of this year.2015 PE may well be under 10 at current $74 share price.
2014 PE just dropped to under 15 based on these earnings and rest of this year.2015 PE may well be under 10 at current $74 share price.
Recent GILD News
- Gilead Sciences to Release First Quarter 2026 Financial Results on Thursday, May 7, 2026 • Business Wire • 04/22/2026 08:05:00 PM
- Form SC TO-T/A - Tender offer statement by Third Party: [Amend] • Edgar (US Regulatory) • 04/17/2026 01:00:24 PM
- Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer • Business Wire • 04/17/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/16/2026 10:41:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/16/2026 10:40:11 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/15/2026 08:12:22 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/15/2026 08:08:03 PM
- PEPFAR and The Global Fund Make Additional Investment in Gilead’s Lenacapavir for HIV Prevention to Further Expand Access • Business Wire • 04/14/2026 04:00:00 PM
- Tempus AI Shares Gain After Expanded Partnership with Gilead • IH Market News • 04/10/2026 01:34:23 PM
- Gilead to Acquire Tubulis Adding Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline • Business Wire • 04/07/2026 12:30:00 PM
- Form SC TO-T/A - Tender offer statement by Third Party: [Amend] • Edgar (US Regulatory) • 04/01/2026 08:34:18 PM
- Gilead Extends Tender Offer to Acquire Arcellx • Business Wire • 04/01/2026 08:13:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/30/2026 09:59:52 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/27/2026 08:03:17 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 03/26/2026 10:40:06 PM
- Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases • Business Wire • 03/23/2026 10:15:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/20/2026 08:01:13 PM
- Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care • PR Newswire (Canada) • 03/19/2026 02:00:00 PM
- Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care • PR Newswire (US) • 03/19/2026 02:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/17/2026 10:56:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/17/2026 10:14:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/16/2026 08:06:49 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/16/2026 08:06:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/12/2026 08:45:40 PM
